Headlands Technologies LLC Trims Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Headlands Technologies LLC cut its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 76.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 3,087 shares of the life sciences company’s stock after selling 9,862 shares during the quarter. Headlands Technologies LLC’s holdings in Integra LifeSciences were worth $134,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Signaturefd LLC raised its holdings in Integra LifeSciences by 248.5% in the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock valued at $25,000 after acquiring an additional 415 shares during the last quarter. Gladius Capital Management LP acquired a new position in Integra LifeSciences in the third quarter valued at $47,000. Covestor Ltd lifted its position in Integra LifeSciences by 82.5% during the third quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock worth $78,000 after buying an additional 921 shares during the period. International Assets Investment Management LLC purchased a new stake in Integra LifeSciences in the 4th quarter valued at about $190,000. Finally, Empirical Asset Management LLC acquired a new position in shares of Integra LifeSciences during the 4th quarter valued at about $212,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Trading Up 3.2 %

NASDAQ:IART opened at $29.24 on Tuesday. Integra LifeSciences Holdings Co. has a 12-month low of $27.18 and a 12-month high of $56.21. The firm has a market capitalization of $2.30 billion, a P/E ratio of 35.23, a P/E/G ratio of 0.85 and a beta of 1.12. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18. The business has a 50 day simple moving average of $35.02 and a 200 day simple moving average of $38.71.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The firm had revenue of $397.00 million during the quarter, compared to the consensus estimate of $399.30 million. During the same quarter in the prior year, the business earned $0.94 earnings per share. The company’s revenue for the quarter was down .3% compared to the same quarter last year. Equities research analysts predict that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current year.

Wall Street Analysts Forecast Growth

IART has been the topic of several research analyst reports. Truist Financial decreased their target price on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a research report on Friday, March 1st. JMP Securities cut their price objective on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a report on Thursday, February 29th. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price for the company in a research report on Wednesday, April 3rd. Finally, StockNews.com cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Friday, April 5th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $44.89.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.